Fig. 5

DIM treatment resulted in the reduction of miR-21 which inhibited the expansion and function of MDSC. A Relative miR-21 level in BM-induced MDSCs (in the condition of 40 ng/ml GM-CSF and 40 ng/ml IL-6 treated for 4 days) and B in the primary spleen MDSCs from 4T1 tumor-bearing mice after treated with DIM. C The percentage of total MDSCs and their subsets in BM-derived/induced MDSCs from WT mice and miR-21^−/− mice. D Relative mRNA levels of Arg1 and iNOS were monitored by qRT-PCR in BM- induced MDSCs from WT or miR-21^−/− mice. E BM cell or BM-induced MDSCs from WT or miR-21^−/− mice were cocultured with CFSE-labeled CD4⁺ and CD8⁺ T cells at a 1:2 ratio for 3 days, and T cell proliferation rate was evaluated by flow cytometry. F Primary MDSCs from bone marrow, blood, spleen and tumor were analyzed by flow cytometry in WT or miR-21^−/− 4T1 tumor-bearing mice. G Relative mRNA levels of Arg1 and iNOS in MDSCs from spleen of WT or miR-21^−/− 4T1 tumor-bearing mice. Data are representative results from three independent experiments and the results are expressed as the mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001. T-MDSC: total MDSCs; M-MDSC: monocytic MDSC; G-MDSC: granulocytic MDSC